Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
Eric D Bateman,1 Christopher O’Brien,2 Paul Rugman,2 Sally Luke,2 Stefan Ivanov,2 Mohib Uddin2,3 1Department of Medicine, University of Cape Town, Cape Town, 7700, South Africa; 2Research and Development, 3Respiratory, Inflammation, and Autoimmunity, IMED Biotech Unit, AstraZeneca, Gothenb...
Saved in:
Main Authors: | Bateman ED (Author), O'Brien C (Author), Rugman P (Author), Luke S (Author), Ivanov S (Author), Uddin M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
by: Kuna P, et al.
Published: (2016) -
CRTH2 antagonists in asthma: current perspectives
by: Singh D, et al.
Published: (2017) -
Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma
by: Sasikala Kumaravel, et al.
Published: (2014) -
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)
by: Bjermer L, et al.
Published: (2015) -
An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
by: Yousif S. Alakeel, et al.
Published: (2022)